Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta-analysis and metaregression.

Singh, Ashutosh Kumar; Alagarsamy, Ragavi; Chaulagain, Rajib; Singh, Abanish; Sapkota, Dipak; Thavaraj, Selvam; Singh, Rabindra P

Singh, Ashutosh Kumar; Alagarsamy, Ragavi; Chaulagain, Rajib; Singh, Abanish; Sapkota, Dipak; Thavaraj, Selvam; Singh, Rabindra P.

Afiliação

Singh AK; Department of Oral and Maxillofacial Surgery, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Alagarsamy R; Department of Burns, Plastic and Maxillofacial Surgery, Safdarjung Hospital, New Delhi, India.
Chaulagain R; Department of Oral Biology, Chitwan Medical College, Bharatpur, Nepal.
Singh A; Department of Community Dentistry, National Medical College, Birgunj, Nepal.
Sapkota D; Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.
Thavaraj S; Department of Oral Pathology, Guy's Hospital, London, UK.
Singh RP; Department of Oral and Maxillofacial Surgery, University Hospital Southampton, Southampton, UK.

J Oral Pathol Med ; 52(10): 895-903, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37872712

Assuntos

Ameloblastoma; Humanos; Masculino; Feminino; Ameloblastoma/genética; Ameloblastoma/patologia; Proteínas Proto-Oncogênicas B-raf/genética; Mutação; Terapia de Alvo Molecular

Palavras-chave

BRAF mutation; ameloblastoma; immunotherapy; jaw tumour

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ameloblastoma Tipo de estudo: Systematic_reviews Limite: Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google